Drug Profile
Seraprevir - Ginkgo Pharma
Alternative Names: GP-205Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Ginkgo Pharma
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hepatitis C
Most Recent Events
- 25 Jul 2022 Seraprevir is still in phase III trial for Hepatitis C (Combination therapy, In adults, In the elderly) in China (PO) (NCT04001608)
- 22 Apr 2022 Phase III development is ongoing in China
- 29 Aug 2020 Ginkgopharma completes a phase III trial in Hepatitis C (Combination therapy, In adults, In the elderly) in China (PO) (NCT04001608)